View in EDS HTML Full Text PDF Full Text

The immediate-early protein 1 of human herpesvirus 6B interacts with NBS1 and inhibits ATM signaling.

Saved in:
Bibliographic Details
Title: The immediate-early protein 1 of human herpesvirus 6B interacts with NBS1 and inhibits ATM signaling.
Authors: Collin V; Division of Infectious Disease and Immunity, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1V 4G2, Canada.; Department of Microbiology, Infectious Disease and Immunology, Faculty of Medicine, Université Laval, Quebec City, QC, G1V 0A6, Canada., Biquand É; Oncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.; Department of Molecular biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec City, QC, G1V 0A6, Canada.; Université Laval Cancer Research Center, Université Laval, Quebec City, QC, G1R 3S3, Canada.; INSERM, Centre d'Étude des Pathologies Respiratoires (CEPR), UMR 1100, Université de Tours, Tours, France., Tremblay V; Oncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.; Department of Molecular biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec City, QC, G1V 0A6, Canada.; Université Laval Cancer Research Center, Université Laval, Quebec City, QC, G1R 3S3, Canada., Lavoie ÉG; Oncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.; Université Laval Cancer Research Center, Université Laval, Quebec City, QC, G1R 3S3, Canada., Blondeau A; Oncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.; Université Laval Cancer Research Center, Université Laval, Quebec City, QC, G1R 3S3, Canada., Gravel A; Division of Infectious Disease and Immunity, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1V 4G2, Canada.; Department of Microbiology, Infectious Disease and Immunology, Faculty of Medicine, Université Laval, Quebec City, QC, G1V 0A6, Canada., Galloy M; Oncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.; Department of Molecular biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec City, QC, G1V 0A6, Canada.; Université Laval Cancer Research Center, Université Laval, Quebec City, QC, G1R 3S3, Canada., Lashgari A; Oncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.; Department of Molecular biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec City, QC, G1V 0A6, Canada.; Université Laval Cancer Research Center, Université Laval, Quebec City, QC, G1R 3S3, Canada., Dessapt J; Oncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.; Department of Molecular biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec City, QC, G1V 0A6, Canada.; Université Laval Cancer Research Center, Université Laval, Quebec City, QC, G1R 3S3, Canada., Côté J; Oncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.; Department of Molecular biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec City, QC, G1V 0A6, Canada.; Université Laval Cancer Research Center, Université Laval, Quebec City, QC, G1R 3S3, Canada., Flamand L; Division of Infectious Disease and Immunity, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1V 4G2, Canada. louis.flamand@crchudequebec.ulaval.ca.; Department of Microbiology, Infectious Disease and Immunology, Faculty of Medicine, Université Laval, Quebec City, QC, G1V 0A6, Canada. louis.flamand@crchudequebec.ulaval.ca., Fradet-Turcotte A; Oncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada. amelie.fradet-turcotte@crchudequebec.ulaval.ca.; Department of Molecular biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec City, QC, G1V 0A6, Canada. amelie.fradet-turcotte@crchudequebec.ulaval.ca.; Université Laval Cancer Research Center, Université Laval, Quebec City, QC, G1R 3S3, Canada. amelie.fradet-turcotte@crchudequebec.ulaval.ca.
Source: EMBO reports [EMBO Rep] 2024 Feb; Vol. 25 (2), pp. 725-744. Date of Electronic Publication: 2024 Jan 02.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 100963049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1469-3178 (Electronic) Linking ISSN: 1469221X NLM ISO Abbreviation: EMBO Rep Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1469-3178
DOI:10.1038/s44319-023-00035-z